Claims
- 1. A method of improving memory consolidation in a human, comprising the step of administering at least one member selected from the group consisting of 1-amphetamine and 1-methamphetamine to a human having an impairment in memory consolidation.
- 2. The method of claim 1, wherein 1-amphetamine is administered, and wherein the 1-amphetamine is administered as a component of a composition that includes at least about 80 mole percent 1-amphetamine relative to a total amphetamine content of the composition.
- 3. The method of claim 1, wherein 1-methamphetamine is administered, and wherein the 1-methamphetamine is administered as a component of a composition that includes at least about 80 mole percent 1-methamphetamine relative to a total methamphetamine content of the composition.
- 4. The method of claim 1, wherein the impairment in memory consolidation in the human is determined by a Rey Auditory Verbal Learning Test.
- 5. The method of claim 1, wherein 1-amphetamine and 1-methamphetamine is administered in a single dose.
- 6. The method of claim 5, wherein the single dose is a dose of at least about a 0.01 mg dose.
- 7. The method of claim 1, wherein the 1-amphetamine and 1-methamphetamine is administered in multiple doses.
- 8. The method of claim 7, wherein each dose of the multiple doses is administered at a dose of at least about a 0.01 mg dose.
- 9. A method of improving memory consolidation in a human, comprising the step of administering at least one member selected from the group consisting of 1-amphetamine and 1-methamphetamine to a human having an impairment in memory consolidation, wherein the 1-amphetamine is administered as a component of a composition that includes at least about 80 mole percent 1-amphetamine relative to a total amphetamine content in the composition and the 1-methamphetamine is administered as a component of a composition that includes at least about 80 mole percent 1-methamphetamine relative to a total methamphetamine content in the composition.
- 10. The method of claim 9, wherein the impairment in memory consolidation in the human is determined by a Rey Auditory Verbal Learning Test.
- 11. The method of claim 9, wherein the 1-amphetamine and 1-methamphetamine is administered as a single dose.
- 12. The method of claim 11, wherein the single dose is a dose of at least about a 0.01 mg dose.
- 13. The method of claim 9, wherein the 1-amphetamine and 1-methamphetamine is administered in multiple doses.
- 14. The method of claim 13, wherein each dose of the multiple doses is administered at a dose of at least about a 0.01 mg dose.
- 15. A method of improving memory consolidation in a human, comprising the step of administering at least one member selected from the group consisting of 1-amphetamine and 1-methamphetamine to a human having an impairment in memory consolidation, wherein the 1-amphetamine is administered as a component of a composition that includes at least about 90 mole percent 1-amphetamine relative to a total amphetamine content in the composition and the 1-methamphetamine is administered as a component of a composition that includes at least about 90 mole percent 1-methamphetamine relative to a total methamphetamine content in the composition.
- 16. A method of improving memory consolidation in a human, comprising the steps of:
a) assessing the degree of an impairment in memory consolidation in a human; b) administering at least one member selected from the group consisting of 1-amphetamine and 1-methamphetamine to the human; and c) determining the improvement in memory consolidation after administering the 1-amphetamine and 1-methamphetamine to the human.
- 17. The method of claim 16, further including the step of comparing the impairment in memory consolidation in the human before administering the 1-amphetamine and 1-methamphetamine to the improvement in memory consolidation in the human after administering the 1-amphetamine and 1-methamphetamine.
- 18. The method of claim 16, wherein memory consolidation is assessed and determined by a Rey Auditory Verbal Learning Test.
- 19. The method of claim 16, wherein the 1-amphetamine and 1-methamphetamine is administered in a dose of at least about a 0.01 mg dose.
- 20. The method of claim 16, wherein 1-amphetamine is administered, and wherein the 1-amphetamine is administered as a component of a composition that includes at least about 80 mole percent 1-amphetamine relative to a total amphetamine content of the composition.
- 21. The method of claim 16, wherein 1-methamphetamine is administered, and wherein the 1-methamphetamine is administered as a component of a composition that includes at least about 80 mole percent 1-methamphetamine relative to a total methamphetamine content of the composition.
- 22. The method of claim 16, wherein the 1-amphetamine and 1-methamphetamine is administered in a single dose.
- 23. The method of claim 16, wherein the 1-amphetamine and 1-methamphetamine is administered in multiple doses.
Priority Claims (1)
Number |
Date |
Country |
Kind |
PCT/US01/45793 |
Oct 2001 |
WO |
|
RELATED APPLICATIONS
[0001] This application is a continuation-in-part of U.S. application Ser. No. 10/139,606, filed May 2, 2002, which is a continuation-in-part of U.S. application Ser. No. 10/003,740 filed Oct. 31, 2001, which claims the benefit of U.S. Provisional Application No. 60/245,323 filed on Nov. 1, 2000 and claims priority to International Application PCT/US01/45793, filed Oct. 31, 2001, which designates the United States and was published in English. The teachings of the above applications are incorporated herein by reference in their entirety.
Provisional Applications (1)
|
Number |
Date |
Country |
|
60245323 |
Nov 2000 |
US |
Continuation in Parts (2)
|
Number |
Date |
Country |
Parent |
10139606 |
May 2002 |
US |
Child |
10444970 |
May 2003 |
US |
Parent |
10003740 |
Oct 2001 |
US |
Child |
10139606 |
May 2002 |
US |